These data from both combination trials indicate that the dual pharmacological inhibition of CRL4 and MEK1/2 outperforms KH‐4‐43 and trametinib as single agents and that these inhibitors cooperate to enhance each other's antitumor activity and may provide benefits in both cisplatin‐sensitive and cisplatin‐resistant ovarian cancer contexts. This evidence concerns the gene MAP2K1 and ovarian cancer.